DAFNA Capital Management’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

DAFNA Capital Management’s Portfolio FOMX Stock Details FOMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-305,500	Closed	-$929K	–	94
2019 Q3	$929K	Sell	305,500 -502,500	-62%	-$1.41M	0.35%	59
2019 Q2	$1.92M	Hold	808,000	–	–	0.72%	38
2019 Q1	$3.03M	Hold	808,000	–	–	1.31%	27
2018 Q4	$2.9M	Hold	808,000	–	–	1.44%	24
2018 Q3	$4.63M	Buy	808,000 +470,000	+139%	+$2.69M	1.9%	17
2018 Q2	$1.69M	Buy	338,000 +2,500	+0.7%	+$12.9K	0.79%	35
2018 Q1	$1.72M	Sell	335,500 -17,241	-5%	-$104K	0.84%	34
2017 Q4	$2.12M	Buy	352,741 +94,074	+36%	+$566K	1.14%	30
2017 Q3	$1.44M	Sell	258,667 -97,000	-27%	-$501K	0.89%	37
2017 Q2	$1.65M	Buy	355,667 +30,000	+9%	+$134K	1.18%	30
2017 Q1	$1.61M	Buy	325,667 +57,600	+21%	+$554K	1.36%	27
2016 Q4	$2.98M	Sell	268,067 -10,000	-4%	-$94.1K	2.61%	11
2016 Q3	$2.58M	Buy	278,067 +85,500	+44%	+$715K	1.79%	18
2016 Q2	$1.22M	Buy	192,567 +73,896	+62%	+$490K	0.97%	35
2016 Q1	$774K	Buy	118,671 +57,901	+95%	+$373K	0.67%	42
2015 Q4	$493K	Buy	+60,770	New	+$454K	0.44%	57

Other funds holding FOMX

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

DAFNA Capital Management's FOMX Position: Q4 2019 in Review

DAFNA Capital Management sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q4 2019, closing a stake of 305,500 shares — an estimated $929K sold.

DAFNA Capital Management first reported a position in FOMX in Q4 2015 and held it in 16 quarters. The position peaked at $4.63M in Q3 2018. 65 funds tracked by Wall St. Rank hold FOMX as of Q4 2019.

DAFNA Capital Management reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q4 2019 after selling out during the quarter.
DAFNA Capital Management sold 305,500 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q4 2019, an estimated $929K.
DAFNA Capital Management first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q4 2015 and held it in 16 quarters.
DAFNA Capital Management's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $4.63M in Q3 2018.
65 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q4 2019.

Based on DAFNA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.